Raymond James & Associates Atara Biotherapeutics, Inc. Transaction History

Raymond James & Associates

$146 Billion
Q1 2024

A detailed history of Raymond James & Associates transactions in Atara Biotherapeutics, Inc. stock. As of the latest transaction made, Raymond James & Associates holds 19,891 shares of ATRA stock, worth $153,359. This represents 0.0% of its overall portfolio holdings.

Number of Shares

19,891

Previous 19,591 1.53%

Holding current value

$153,359

Previous $9,000 44.44%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 22, 2024	BUY	$0.44 - $1.22 $132 - $366	300 Added 1.53%	19,891 $13,000
Q4 2023 Jan 16, 2024	SELL	$0.23 - $1.74 $39,111 - $295,888	-170,051 Reduced 89.67%	19,591 $9,000
Q3 2023 Oct 24, 2023	BUY	$1.41 - $2.31 $3,238 - $5,306	2,297 Added 1.23%	189,642 $280,000
Q2 2023 Jul 25, 2023	SELL	$1.5 - $3.04 $2,337 - $4,736	-1,558 Reduced 0.82%	187,345 $301,000
Q1 2023 Apr 14, 2023	BUY	$2.8 - $5.46 $20,132 - $39,257	7,190 Added 3.96%	188,903 $547,000

Q4 2022 Feb 08, 2023	SELL	$2.85 - $5.18 $7,481 - $13,597	-2,625 Reduced 1.42%	181,713 $596,000
Q3 2022 Oct 25, 2022	BUY	$2.85 - $8.73 $339,477 - $1.04 Million	119,115 Added 182.63%	184,338 $697,000
Q2 2022 Aug 12, 2022	BUY	$4.69 - $9.84 $305,895 - $641,794	65,223 New	65,223 $508,000
Q2 2020 Jul 28, 2020	SELL	$7.53 - $14.93 $179,003 - $354,915	-23,772 Closed	0 $0
Q1 2020 Apr 21, 2020	BUY	$5.69 - $17.78 $14,828 - $46,334	2,606 Added 12.31%	23,772 $202,000
Q4 2019 Feb 12, 2020	BUY	$10.89 - $16.79 $10,149 - $15,648	932 Added 4.61%	21,166 $349,000
Q3 2019 Nov 07, 2019	SELL	$12.03 - $19.94 $2,682 - $4,446	-223 Reduced 1.09%	20,234 $286,000
Q2 2019 Aug 06, 2019	SELL	$19.05 - $41.04 $103,917 - $223,873	-5,455 Reduced 21.05%	20,457 $411,000
Q1 2019 May 06, 2019	BUY	$28.4 - $41.74 $5,594 - $8,222	197 Added 0.77%	25,912 $1.03 Million
Q4 2018 Feb 11, 2019	SELL	$30.9 - $42.97 $9,733 - $13,535	-315 Reduced 1.21%	25,715 $893,000
Q3 2018 Nov 14, 2018	SELL	$35.05 - $43.5 $13,143 - $16,312	-375 Reduced 1.42%	26,030 $1.08 Million
Q2 2018 Aug 14, 2018	SELL	$35.15 - $51.45 $53,674 - $78,564	-1,527 Reduced 5.47%	26,405 $970,000
Q1 2018 May 14, 2018	BUY	$18.0 - $48.35 $46,926 - $126,048	2,607 Added 10.29%	27,932 $1.09 Million
Q4 2017 Feb 14, 2018	BUY	$13.2 - $18.1 $22,690 - $31,113	1,719 Added 7.28%	25,325 $458,000
Q3 2017 Nov 13, 2017	BUY	$13.25 - $17.05 $159 - $204	12 Added 0.05%	23,606 $391,000
Q2 2017 Aug 14, 2017	BUY	N/A	23,594	23,594 $330,000

Others Institutions Holding ATRA

# of Institutions

Shares Held

85M

Call Options Held

18.4K

Put Options Held

51.3K

View Full List

About Atara Biotherapeutics, Inc.

Ticker ATRA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 94,362,304
Market Cap $728M
Description
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...

More about ATRA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Account

Raymond James & Associates Atara Biotherapeutics, Inc. Transaction History